Gennova overcame technological challenges and launched Tenecteplase for acute myocardial infarction (AMI) – the medical name for a heart attack way back in 2007. The innovation in bio-manufacturing allowed the company to provide this life-saving drug to the Indian market at roughly one-third the price of the innovator’s drug at the time of launch. To date, Elaxim™ has been delivered to > 200,000 patients around the globe with published pharmaco-vigilance data available for 15,222 patients in 2013 and additional 7,668 patients in 2017.
Till August 2016, Alteplase was the only approved treatment for acute ischemic stroke (AIS). In recent clinical trials conducted by Gennova, it has expanded the use of its Tenceteplase for the indication of AIS. Gennova’s Tenectase® is a pioneering product, where first time globally a 3rd generation thrombolytic was approved for stroke. Tenecetase® was included in the list of drugs for emergency care for stroke management in the ‘Guidelines for Prevention and Management of Stroke’, issued by the Ministry of Health and Family Welfare, Govt. of India
As per IMS Health data, Gennova is the market leader for FOUR of the products.
In 2014, Gennova was the first company to launch generic Pegaspargase (HAMSYL®) in India for use in acute lymphoblastic lymphoma (ALL), an orphan indication, at an competitive cost. Since its launch, it has benefited more than 3,000 patients.
